HRPK20030734B3 - A combination comprising combretastatin and anticancer agents - Google Patents

A combination comprising combretastatin and anticancer agents

Info

Publication number
HRPK20030734B3
HRPK20030734B3 HR20030734A HRP20030734A HRPK20030734B3 HR PK20030734 B3 HRPK20030734 B3 HR PK20030734B3 HR 20030734 A HR20030734 A HR 20030734A HR P20030734 A HRP20030734 A HR P20030734A HR PK20030734 B3 HRPK20030734 B3 HR PK20030734B3
Authority
HR
Croatia
Prior art keywords
combination
combretastatin
anticancer agents
effective amount
metabotites
Prior art date
Application number
HR20030734A
Other languages
English (en)
Croatian (hr)
Inventor
Bissery Marie-Christine
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HRP20030734A2 publication Critical patent/HRP20030734A2/hr
Publication of HRPK20030734B3 publication Critical patent/HRPK20030734B3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
HR20030734A 2001-03-15 2002-03-15 A combination comprising combretastatin and anticancer agents HRPK20030734B3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27562701P 2001-03-15 2001-03-15
PCT/EP2002/003322 WO2002074229A2 (en) 2001-03-15 2002-03-15 A combination comprising combretastatin and anticancer agents

Publications (2)

Publication Number Publication Date
HRP20030734A2 HRP20030734A2 (en) 2005-06-30
HRPK20030734B3 true HRPK20030734B3 (en) 2006-11-30

Family

ID=23053164

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030734A HRPK20030734B3 (en) 2001-03-15 2002-03-15 A combination comprising combretastatin and anticancer agents

Country Status (37)

Country Link
US (4) US20020183266A1 (https=)
EP (1) EP1439839B8 (https=)
JP (1) JP4991107B2 (https=)
KR (1) KR100849610B1 (https=)
CN (2) CN1935134B (https=)
AR (1) AR032989A1 (https=)
AT (1) ATE433750T1 (https=)
AU (1) AU2002304574B2 (https=)
BR (1) BR0208017A (https=)
CA (2) CA2673449C (https=)
CY (1) CY1109364T1 (https=)
CZ (1) CZ302451B6 (https=)
DE (1) DE60232673D1 (https=)
DK (1) DK1439839T3 (https=)
EA (1) EA006316B1 (https=)
EC (1) ECSP034766A (https=)
ES (1) ES2327617T3 (https=)
HR (1) HRPK20030734B3 (https=)
HU (1) HU228510B1 (https=)
IL (2) IL157891A0 (https=)
MA (1) MA27000A1 (https=)
ME (2) ME00056B (https=)
MX (1) MXPA03007552A (https=)
NO (1) NO332661B1 (https=)
NZ (1) NZ527526A (https=)
PE (1) PE20020909A1 (https=)
PL (1) PL205728B1 (https=)
PT (1) PT1439839E (https=)
RS (1) RS50682B (https=)
SI (1) SI1439839T1 (https=)
SK (1) SK287908B6 (https=)
TN (1) TNSN03060A1 (https=)
TW (1) TWI306028B (https=)
UA (1) UA75127C2 (https=)
UY (1) UY27208A1 (https=)
WO (2) WO2004037258A1 (https=)
ZA (1) ZA200306789B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267255T3 (es) * 1998-04-03 2007-03-01 Ajinomoto Co., Inc. Agentes antitumorales.
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN1319978C (zh) * 2005-04-06 2007-06-06 西南合成制药股份有限公司 康布瑞汀化合物的制备方法
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US20080104512A1 (en) * 2006-10-31 2008-05-01 Motorola, Inc. Method and apparatus for providing realtime feedback in a voice dialog system
DK2219451T3 (en) * 2007-11-21 2015-01-12 Oxigene Inc A method for the treatment of hematopoietic neoplasms
WO2009103076A1 (en) * 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) * 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EP2397135A1 (en) 2010-06-18 2011-12-21 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2481404A1 (en) 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
AU2011266635A1 (en) 2010-06-18 2013-01-10 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2407161A1 (en) 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ES2267255T3 (es) * 1998-04-03 2007-03-01 Ajinomoto Co., Inc. Agentes antitumorales.
US6242770B1 (en) * 1998-08-31 2001-06-05 Gary Bela Bronner Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
HUP0302629A3 (en) * 2000-10-27 2005-05-30 Aventis Pharma Sa Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US6466448B1 (en) * 2001-06-11 2002-10-15 Network Appliance, Inc. Riser board retaining and air ducting structure for printed circuit boards

Also Published As

Publication number Publication date
EP1439839A1 (en) 2004-07-28
MXPA03007552A (es) 2004-10-15
CY1109364T1 (el) 2014-07-02
PL374406A1 (en) 2005-10-17
HK1067039A1 (en) 2005-04-01
US20030060429A1 (en) 2003-03-27
TNSN03060A1 (en) 2005-12-23
CN1290504C (zh) 2006-12-20
ME00056B (me) 2010-06-10
IL157891A0 (en) 2004-03-28
CA2470484A1 (en) 2004-05-06
WO2004037258A1 (en) 2004-05-06
BR0208017A (pt) 2004-12-07
IL157891A (en) 2010-06-16
CN1935134B (zh) 2010-12-15
US20050075295A1 (en) 2005-04-07
ZA200306789B (en) 2005-02-23
AU2002304574B2 (en) 2005-09-15
NO20034022D0 (no) 2003-09-11
TWI306028B (en) 2009-02-11
UY27208A1 (es) 2002-08-30
YU71303A (sh) 2006-08-17
CZ302451B6 (cs) 2011-05-25
EP1439839B1 (en) 2009-06-17
NO20034022L (no) 2003-09-11
KR20040067866A (ko) 2004-07-30
HUP0600233A2 (en) 2008-06-30
WO2002074229A2 (en) 2002-09-26
MA27000A1 (fr) 2004-12-20
UA75127C2 (en) 2006-03-15
US20020183266A1 (en) 2002-12-05
US20070149476A1 (en) 2007-06-28
AU2002304574A1 (en) 2004-05-13
ATE433750T1 (de) 2009-07-15
DK1439839T3 (da) 2009-10-05
PT1439839E (pt) 2009-09-03
NO332661B1 (no) 2012-11-26
CA2673449C (en) 2011-10-18
SI1439839T1 (sl) 2011-09-30
SK11552003A3 (sk) 2004-03-02
DE60232673D1 (de) 2009-07-30
HU228510B1 (en) 2013-03-28
PL205728B1 (pl) 2010-05-31
RS50682B (sr) 2010-06-30
EA200301015A1 (ru) 2004-08-26
ES2327617T3 (es) 2009-11-02
KR100849610B1 (ko) 2008-07-31
HUP0600233A3 (en) 2010-03-29
JP4991107B2 (ja) 2012-08-01
EA006316B1 (ru) 2005-10-27
MEP16208A (en) 2010-06-10
ECSP034766A (es) 2003-10-28
AR032989A1 (es) 2003-12-03
JP2005522527A (ja) 2005-07-28
CA2470484C (en) 2009-10-13
NZ527526A (en) 2006-11-30
HRP20030734A2 (en) 2005-06-30
CZ20032476A3 (en) 2004-07-14
CN1935134A (zh) 2007-03-28
CN1547471A (zh) 2004-11-17
CA2673449A1 (en) 2004-05-06
PE20020909A1 (es) 2002-12-09
SK287908B6 (sk) 2012-03-02
EP1439839B8 (en) 2010-09-01
US6933320B2 (en) 2005-08-23

Similar Documents

Publication Publication Date Title
HRPK20030734B3 (en) A combination comprising combretastatin and anticancer agents
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
AR027355A1 (es) Acidos tiazolidincarboxilicos
DE69925133D1 (de) Pyrrolobenzodiazepine
HRP20030831B1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
FR2781218B1 (fr) Compositions pharmaceutiques comprenant des 2-quinolones
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
DE10084671T1 (de) Pharmazeutische Zusammensetzungen
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
SE9802937D0 (sv) Novel compounds
SE0003476D0 (sv) Compounds
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
SE0004827D0 (sv) Therapeutic compounds
AR022719A1 (es) Una composicion sinergica antitumoral.
GEP20115184B (en) Pharmacokinetically improved compounds
ATE317384T1 (de) Lta4 hydrolase-hemmer
DE60003189D1 (de) Synergistische zusammensetzung, die daunorubicin derivate und antimetabolite enthält
DE50211461D1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
SE9902674D0 (sv) New composition
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome
WO2001000240A3 (en) Antitumor compound

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AKOB Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent)
PKB1 Consensual patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120229

Year of fee payment: 11

PK10 Patent expired after termination of 10 years for consensual patent

Effective date: 20120316